Aviragen shares plunge as RSV antiviral flunks a small PhIIa study
The antiviral biotech Aviragen $AVIR says that its experimental RSV therapy BTA585 flunked a small Phase IIa study in volunteers who had been intranasally infected with the virus.
Only about 20 patients were recruited for the study. Divided into three cohorts, two received different doses of BTA585 and the third was treated with a placebo. The primary endpoint was viral load with some secondary endpoints on the severity of RSV disease as measured by 10 RSV-related clinical symptoms and mucus weight.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
